UK markets open in 5 hours 36 minutes

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
87.40+1.40 (+1.63%)
At close: 04:06PM CEST
Full screen
Previous close86.00
Open88.00
Bid84.80 x 0
Ask87.20 x 0
Day's range83.40 - 88.00
52-week range41.30 - 106.50
Volume2,287
Avg. volume6,939
Market cap1.177B
Beta (5Y monthly)1.01
PE ratio (TTM)N/A
EPS (TTM)-9.95
Earnings date07 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Infant Bacterial Therapeutics AB (publ) Interim report January 1 - June 30, 2023

    Message from the CEO Our Phase-III study, the largest of its kind ever conducted, is progressing across 88 hospitals in ten countries. We have now recruited 85% of the patients (1824 out of the planned 2158), and with the current rate of approximately 75 patients per month, we anticipate completing the recruitment by the end of the year. In June, the Data Monitoring Committee (DMC) concluded its scheduled safety analysis of data from the first 1400 recruited patients. The DMC's conclusion is tha

  • Globe Newswire

    New number of shares and votes in IBT

    The number of shares and votes in Infant Bacterial Therapeutics AB (publ) has changed due to the recently completed rights issue (for further information, see the company’s press release on 4 July 2023). Through the rights issue, the number of shares in IBT increased with 2,245,236 (of which 75,547 class A shares and 2,169,689 class B shares) and the number of votes increased with 2,925,159. Today, on the last trading day of the month, there are in total 13,471,420 shares (of which 453,283 class

  • Globe Newswire

    IBT announces outcome of its rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. The Board of Directors of Infant Bacterial Therapeutics AB (publ) (“